Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus rhamnosus plus nystatin vs nystatin for intestinal Candida colonization in low birth weight infants
IRCT20130812014333N175Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of lactobacillus rhamnosus and nystatin (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: Reduction in intestinal Candida albicans colony growth. Started Oct 2021; status: completed.
02
Drugs
lactobacillus rhamnosusnystatin
Beyond the preview
Go deeper on IRCT20130812014333N175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N175.